North America

BridgeBio Oncology Therapeutics posted new Phase 1 data showing its KRAS G12C inhibitor combo achieved a 75% response rate in inhibitor-experienced lung cancer patients.

The Seattle-based biotech will use proceeds to run its ILLUMINATE Phase 2 study of BCB-276 in diffuse intrinsic pontine glioma, a universally fatal

Dyne will present pooled Phase 1/2 data for z-basivarsen against a matched natural history cohort, with registrational topline results due Q1 2027.

The Waltham-based neurodegenerative disease biotech completed its merger with Cyclerion and a $380m private placement, beginning Nasdaq trading under "KRSA" on 9

SPY003 met its primary endpoint in ulcerative colitis, giving Spyre positive Phase 2 monotherapy readouts for all three of its IBD combination components.

Vor Bio has fully enrolled its global Phase 3 gMG study and will initiate a sister trial in ocular myasthenia gravis, with topline data expected

The Nasdaq-listed oncology company has detailed patents covering APR-1051 and ATRN-119, with WEE1 protection potentially running to 2047.

BTT Medical Institute has launched a safety trial of its brain-guided hyperthermia system, citing a single ALS case report as the basis for development.

NorthStrive Biosciences has filed two US patent applications extending its myostatin-targeting probiotic candidates into microgravity-induced muscle atrophy.

The Belgian medtech has begun a 229-patient, five-year US real-world study of its Genio bilateral hypoglossal nerve stimulator, approved by the FDA

Teva Pharmaceutical is issuing EUR and USD senior notes via Dutch finance subsidiaries, with proceeds earmarked primarily for early redemption of existing notes.

A landmark DNA study of Western North Atlantic white sharks has identified three full sibling pairs and seven likely half-sibling pairs, challenging the species'

Zentalis is raising fresh capital via an underwritten public offering to fund trials and pre-commercial activities for its WEE1 inhibitor azenosertib in ovarian cancer.

AMS posted 19% year-on-year Q2 revenue growth to $8.4m, led by a 40% surge in direct patient services across its US and

The NASDAQ-listed MWA device maker posted $9.9m in first-half revenue, with the US now accounting for 27% of sales versus under 2

Cytek will present Full Spectrum Profiling technology at two clinical cytometry conferences in September and October, with a focus on MRD monitoring.

A post-hoc item-level analysis found domain-specific cognitive gains three months after treatment in half of evaluable active-arm participants.

Pulmovant will share Phase 2 results for inhaled sGC activator mosliciguat in PH-ILD at ERS Congress on 8 September 2026.

S&P's upgrade to BBB- means Teva now holds investment-grade ratings from all three major agencies, capping a multi-month credit rehabilitation.

The NASDAQ-listed RNAi oncology biotech will use net proceeds to advance its Phase 2/3 SIL204 trial in locally advanced pancreatic cancer.